Skip to content

Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states.

Hugo R Arias, Avraham Rosenberg, Katarzyna M Targowska-Duda, Dominik Feuerbach, Xiao Juan Yuan, Krzysztof Jozwiak, Ruin Moaddel, Irving W Wainer

The international journal of biochemistry & cell biology September 1, 2010 DOI: 10.1016/j.biocel.2010.05.011 via PubMed

Summary

AI-generated from the abstract

Ibogaine blocks human alpha3beta4-nicotinic acetylcholine receptors (AChRs) by binding to a site in the receptor's ion channel, with about nine times higher potency than phencyclidine (PCP). Ibogaine binds with relatively high affinity (Kd = 0.46 ± 0.06 μM) to a single site in the channel and dissociates more slowly from the desensitized receptor than from the resting one, which may prolong the desensitized state. PCP inhibits ibogaine binding, indicating overlapping binding sites between the serine and valine/phenylalanine rings. The interaction is mainly via van der Waals contacts, with local conformational changes suggested by entropic contributions. These findings suggest ibogaine's mechanism involves stabilizing the receptor in a shut-down state.

Study at a glance

Characteristics Experimental study Peer reviewed
Population Human alpha3beta4-nicotinic acetylcholine receptors
Interventions Ibogaine Phencyclidine
Keywords Ibogaine: ibogaine Human brain receptor Key brain receptors Receptor's channel Desensitized state
Citations 29
Key finding Ibogaine binds with higher potency than PCP to a single site in the human alpha3beta4 AChR ion channel and dissociates more slowly from the desensitized state, likely prolonging receptor desensitization.

Abstract

The interaction of ibogaine and phencyclidine (PCP) with human (h) alpha3beta4-nicotinic acetylcholine receptors (AChRs) in different conformational states was determined by functional and structural approaches including, radioligand binding assays, Ca2+ influx detections, and thermodynamic and kinetics measurements. The results established that (a) ibogaine inhibits (+/-)-epibatidine-induced Ca2+ influx in h(alpha)3beta4 AChRs with approximately 9-fold higher potency than that for PCP, (b) [3H]ibogaine binds to a single site in the h(alpha)3beta4 AChR ion channel with relatively high affinity (Kd = 0.46 +/- 0.06 microM), and ibogaine inhibits [3H]ibogaine binding to the desensitized h(alpha)3beta4 AChR with slightly higher affinity compared to the resting AChR. This is explained by a slower dissociation rate from the desensitized ion channel compared to the resting ion channel, and (c) PCP inhibits [3H]ibogaine binding to the h(alpha)3beta4 AChR, suggesting overlapping sites. The experimental results correlate with the docking simulations suggesting that ibogaine and PCP interact with a binding domain located between the serine (position 6') and valine/phenylalanine (position 13') rings. This interaction is mediated mainly by van der Waals contacts, which is in agreement with the observed enthalpic contribution determined by non-linear chromatography. However, the calculated entropic contribution also indicates local conformational changes. Collectively our data suggest that ibogaine and PCP bind to overlapping sites located between the serine and valine/phenylalanine rings, to finally block the AChR ion channel, and in the case of ibogaine, to probably maintain the AChR in the desensitized state for longer time.

Comments

No comments yet.

Log in to comment